Informed Consent in Direct-to-Patient (DTP) Clinical Trial Delivery Models

In decentralized clinical trials (DCTs), informed consent remains a cornerstone of ethical research. With the advent of Direct-to-Patient (DTP) delivery models, where investigational medicinal products (IMPs) are shipped to patient homes, the process of obtaining and documenting informed consent must adapt. This tutorial offers guidance on structuring informed consent forms (ICFs) and processes to support DTP models while ensuring regulatory compliance and patient safety.

Understanding Informed Consent in a DTP Context

In traditional site-based trials, consent is usually obtained face-to-face under the supervision of investigators. However, in DTP models, trials shift towards remote or electronic interactions. This introduces complexities around:

• Educating patients on home-based drug use
• Explaining logistics, responsibilities, and risks of DTP delivery
• Ensuring proper documentation and comprehension
• Regulatory and ethical compliance

The informed consent process must now account for both therapeutic and logistical risks associated with remote drug access.

Regulatory Expectations and Ethical Framework

Regulators such as the USFDA and EMA emphasize that informed consent must be:

• Given freely without coercion
• Based on complete, understandable information
• Documented through approved means (eConsent or paper)
• Specific to the procedures being performed, including DTP delivery

In a DTP context, this includes disclosure of how and when the IMP will be shipped, who is responsible for receiving it, and what actions the patient must take if delivery fails or the drug is damaged.

Key Elements to Include in the Informed Consent Form (ICF)

The ICF for DTP trials should contain the following additions beyond traditional content:

1. DTP Delivery Information: Method, frequency, carrier, and tracking details.
2. Patient Responsibilities: Storage, reporting of excursions, and return of unused IMP.
3. Risks of Home Delivery: Tampering, delays, loss, exposure to children, etc.
4. Dispute Handling: Steps to take if IMP is not received or damaged.
5. Alternate Plans: Back-up arrangements if DTP becomes unfeasible.

Ensure the language is simple, avoiding technical jargon. Consider readability for audiences with varied education levels.

Using eConsent in DTP Trials

Electronic consent (eConsent) is increasingly accepted and beneficial for DTP models. Benefits include:

• Interactive elements like videos to explain the DTP process
• Built-in comprehension checks
• Real-time investigator support via video or chat
• Audit trails for compliance tracking

However, ensure platforms comply with data privacy laws such as HIPAA, GDPR, and country-specific digital health regulations. You may consult pharma regulatory requirements for jurisdictional nuances.

Investigator Oversight of Informed Consent

Even in remote DTP trials, investigators retain the responsibility of ensuring patients:

• Fully understand the nature and risks of DTP delivery
• Are capable of handling IMP at home (storage, dosing, return)
• Have opportunities to ask questions
• Sign consent forms knowingly and voluntarily

This can be fulfilled through video calls, telephone follow-ups, or recorded confirmations integrated into eConsent platforms.

Patient Education as Part of Consent

Effective informed consent requires strong patient education. Consider integrating:

• FAQs on DTP delivery
• Visual storage instructions (e.g., refrigeration requirements)
• Timelines for expected delivery and return
• 24/7 helpline contact in case of issues

These can be delivered via printed materials, digital apps, or patient portals linked with the trial system and stability testing guidance.

SOPs for Informed Consent in DTP Models

Your organization should develop GMP SOPs or ICH-aligned SOPs covering:

• Consent form review and approvals
• Training investigators on DTP-specific risks
• Procedures for obtaining and verifying consent remotely
• Recordkeeping and updates to consent (e.g., protocol amendments)
• Audit readiness and documentation archiving

Ensure the consent process is auditable and that updates are communicated to all stakeholders.

Checklist: Informed Consent for DTP Models

• Consent includes DTP delivery terms, frequency, and methods
• Patient responsibilities clearly described
• Risks specific to home delivery explained
• eConsent platform is 21 CFR Part 11 compliant (if used)
• Investigator reviews and confirms patient understanding
• SOPs updated to reflect DTP-specific procedures
• All consent documentation included in TMF

Conclusion

Informed consent for DTP delivery models must be comprehensive, patient-centered, and compliant with international ethical standards. As clinical trials move into homes, so too must the responsibility of educating and empowering patients through the consent process. By embedding clarity, transparency, and technology into the consent strategy, sponsors can uphold ethical standards and ensure trial integrity across decentralized frameworks.